Today, a Director at Allscripts (NASDAQ: MDRX), Michael Klayko, bought shares of MDRX for $50.08K.
This is Klayko’s first transaction since reporting a Sell transaction on PMCS back in December 2015 Following this transaction Michael Klayko’s holding in the company was increased by 3.38% to a total of $1.48 million.
See today’s analyst top recommended stocks >>
Based on Allscripts’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $514 million and GAAP net loss of $39.87 million. In comparison, last year the company earned revenue of $413 million and had a GAAP net loss of $19.98 million. Currently, Allscripts has an average volume of 2.44M.
22 different firms, including Argus Research and Avondale, currently also have a Buy rating on the stock. Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $16.80, reflecting a -26.0% downside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allscripts Healthcare Solutions, Inc. engages in the provision of clinical, financial, connectivity, information solutions, and related professional services. It operates through the following segments: Clinical and Financial Solutions; Population Health; and Netsmart.
